In this third episode of a four-part Double Take video miniseries on depression
from the New England Journal of Medicine, Drs. Sanacora, Nikayin, and Cristancho
discuss the role neuroplasticity may play in the pathogenesis of depression and
the benefits to patients of advanced therapies for treatment-resistant depression,
such as electroconvulsive therapy and transcranial magnetic stimulation.
An overview of emerging evidence for the use of ketamine, esketamine, and
psilocybin as new or potential treatments is also examined.
For further reading, the following articles, referenced in this video, are
available at the Journal’s website: Esketamine for Treatment-Resistant Depression
— First FDA-Approved Antidepressant in a New Class (Kim et al., in the July 4,
2019, issue; https://www.nejm.org/doi/full/10.1056/NEJMp1903305 ), Electroconvulsive Therapy (Espinoza and Kellner, in the February
17, 2022, issue; https://www.nejm.org/doi/full/10.1056/NEJMra2034954 ), Psilocybin in Treatment-Resistant Depression (Madras; https://www.nejm.org/doi/full/10.1056/NEJMe2210975 ) and
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
(Goodwin et al.; https://www.nejm.org/doi/full/10.1056/NEJMoa2206443 ) (both in the November 3, 2022, issue), Ketamine versus ECT for
Nonpsychotic Treatment-Resistant Major Depression (Anand et al., in the June
22, 2023, issue; https://www.nejm.org/doi/full/10.1056/NEJMoa2302399 ), and Esketamine Nasal Spray versus Quetiapine for Treatment
-Resistant Depression (Reif et al., in the October 5, 2023, issue; https://www.nejm.org/doi/full/10.1056/NEJMoa2304145 ).
#depression #depressionmanagement #mentalhealth #mentalillness #nejm
The _New England Journal of Medicine_ is the world’s leading general medical
journal. Continuously published for over 200 years, the _Journal_ publishes
peer-reviewed research along with interactive clinical content for physicians,
educators, and the global medical community at https://NEJM.org.